Skip to content

Inventories at other companies

Gilead Sciences logo
Gilead SciencesGILD
$2.42B+20.1%
Alkermes logo
AlkermesALKS
$336.7M+83.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$5.56M-51.7%
TG Therapeutics logo
TG TherapeuticsTGTX
$26.35M-83.3%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s inventories?
Mirum Pharmaceuticals, Inc. (MIRM) reported inventories of $25.52M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s inventories changed year-over-year?
Mirum Pharmaceuticals, Inc.'s inventories increased by 13.8% year-over-year, from $22.42M to $25.52M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s inventories?
Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s inventories has grown at a 181.0% compound annual growth rate (CAGR), from $1.51M to $94.27M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.